白蛋白紫杉醇联合奈达铂同步放化疗治疗宫颈癌患者的效果及安全性  

Efficacy and Safety of Albumin-bound Paclitaxel Combined with Nedaplatin in Concurrent Chemoradiotherapy for Cervical Cancer

作　　者：刘芸 LIU Yun(Department of Gynecology,Xinxiang First People’s Hospital,Xinxiang 453000,China)

机构地区：[1]新乡市第一人民医院妇科,河南新乡453000

出　　处：《实用临床医学（江西）》2024年第6期39-42,共4页Practical Clinical Medicine

摘　　要：目的探讨白蛋白紫杉醇联合奈达铂同步放化疗对宫颈癌患者的疗效及安全性,以期为临床提供治疗方案,改善患者生存质量。方法选取2021年8月至2023年8月就诊于新乡市第一人民医院的80例宫颈癌患者,按随机数字表法分为研究组和参照组各40例,其中参照组给予单纯放射治疗,研究组在参照组基础上加用白蛋白紫杉醇联合奈达铂同步化疗,比较2组疾病控制率、治疗前与治疗6周后生存质量评分、中位无进展生存时间(PFS)、2年生存率及不良反应发生情况。结果研究组疾病控制率[95.00%(38/40)]明显高于参照组[80.00%(32/40)](P<0.05);与参照组比较,研究组治疗6周后社会功能、躯体功能、心理功能、物质功能评分及生存质量总分较高(P<0.05);随访2年,研究组PFS及2年生存率明显高于参照组(P<0.05);2组治疗期间骨髓抑制Ⅲ-Ⅳ级、消化道反应、肝肾功能损害、脱发、周围神经炎等不良反应比较差异均无统计学意义(P>0.05),研究组骨髓抑制Ⅰ-Ⅱ级发生率低于参照组(P<0.05)。结论白蛋白紫杉醇联合奈达铂同步放化疗可提高中晚期宫颈癌患者疾病控制率,促进患者生存质量改善,能有效降低治疗期间骨髓抑制发生率,具有良好安全性。Objective To investigate the efficacy and safety of albumin-bound paclitaxel combined with nedaplatin in concurrent chemoradiotherapy for patients with cervical cancer,aiming to provide clinical treatment options and improve patients’quality of life.Methods 80 cervical cancer patients who visited Xinxiang First People’s Hospital from August 2021 to August 2023 were selected and randomly divided into a study group and a control group with 40 patients in each group using a random number table method.The control group received radiotherapy alone,while the study group received concurrent chemotherapy with albumin-bound paclitaxel and nedaplatin on the basis of the control group’s treatment.The disease control rate,quality of life scores before treatment and after 6 weeks of treatment,median progression-free survival(PFS),2-year survival rate,and adverse reactions were compared between the 2 groups.Results The disease control rate in the study group[95.00%(38/40)]was significantly higher than that in the control group[80.00%(32/40)](P<0.05).Compared with the control group,the study group had higher scores for social function,somatic function,psychological function,material function,and overall quality of life after 6 weeks of treatment(P<0.05);after 2 years of follow-up,the PFS and 2-year survival rate in the study group were significantly higher than those in the control group(P<0.05).There were no statistically significant differences in adverse reactions such as myelosuppression gradeⅢ-Ⅳ,gastrointestinal reactions,liver and kidney function impairment,alopecia,and peripheral neuropathy between the 2 groups during treatment(P>0.05).However,the incidence of myelosuppression gradeⅠ-Ⅱin the study group was lower than that in the control group(P<0.05).Conclusion Concurrent chemoradiotherapy with albumin-bound paclitaxel and nedaplatin can improve the disease control rate and enhance quality of life for patients with intermediate and advanced cervical cancer.It can effectively reduce the incidence of myelosu

关 键 词：宫颈癌 白蛋白紫杉醇 奈达铂 不良反应 生存质量 

分 类 号：R737.33[医药卫生—肿瘤]